Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Diwakar Davar"'
Autor:
Yana G. Najjar, Diwakar Davar, Xi Yang, Saba Shaikh, Greg M. Delgoffe, Yan Zang, Amy Rose, John M. Kirkwood, Hassane M. Zarour, Hong Wang, Jason J. Luke, Cindy Sander
Publikováno v:
Regular and young investigator award abstracts.
Background Immunotherapy has changed the treatment landscape for melanoma, although many patients (pts) do not respond to treatment. While there are likely multiple mechanisms of resistance at play, one key mechanism is the generation of an immunosup
Autor:
Hassane M. Zarour, Joe-Marc Chauvin, Richelle DeBlasio, Diwakar Davar, Ornella Pagliano, Douglas J. Hartman, Arivarasan Karunamurthy, Amy Rose, John M. Kirkwood, Quanquan Ding
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background Neoadjuvant PD-1 blockade produces major pathological responses (MPR) in ~30% of patients (pts) with high-risk resectable melanoma (MEL) with durable relapse-free benefit, and increased circulating activated CD8+ T cells.1 2 CMP-001 is a t
Autor:
Carmine Menna, Amirin Dzutsev, Marie Vétizou, Jonathan H. Badger, John M. Kirkwood, John McCullogh, Hassane M. Zarour, Giorgio Trinchieri, Diwakar Davar, Ornella Pagliano
Publikováno v:
Cancer Immunology Research. 7:IA38-IA38
Immunotherapy with blocking anti-PD1 monoclonal antibodies (a PD1 mAbs) has become one of the most potent therapies of melanoma, providing extended clinical benefits to 30-40% advanced melanoma patients. There is substantial evidence that pre-existin